Compare Roblox Corp (RBLX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Viatris Inc — how do they compare? Roblox Corp trades at $49.6 (market cap $37.59B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Roblox Corp is the larger of the two by market cap, and Viatris Inc pays a 2.73% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| RBLX | VTRS | |
|---|---|---|
Market Cap | $37.59B | $20.50B |
Sector | Media | Health |
52-Week High | $141.56 | $17.59 |
52-Week Low | $41.30 | $8.74 |
Enterprise Value | $36.18B | $32.71B |
Dividend Yield | — | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
